Literature DB >> 1311993

Epstein-Barr virus and HIV play no direct role in persistent generalized lymphadenopathy syndrome.

M J Boyle1, T B Sculley, D A Cooper, J J Turner, R Penny, W A Sewell.   

Abstract

Persistent generalized lymphadenopathy (PGL) and polyclonal B cell activation are features of infection with HIV. Epstein-Barr virus (EBV) and HIV are known to activate B cells in vitro, but whether they are important B cell activators in patients infected with HIV is less clear. In this study, lymph node tissue was obtained from 10 patients with PGL and assessed for evidence of EBV and HIV gene sequences. DNA was extracted and specific viral gene sequences identified using the polymerase chain reaction (PCR). EBV sequences were difficult to detect in the PGL tissue, with a signal intensity similar to that of other benign and malignant lymphoid conditions not associated with EBV. HIV sequences were also rare in the PGL tissue, consistent with HIV infection of the small number of peripheral blood cells and nodal T cells likely to be present in such a sample. These findings suggest that the polyclonal B cell activation typical of HIV is not driven by direct EBV or HIV infection of B cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311993      PMCID: PMC1554330          DOI: 10.1111/j.1365-2249.1992.tb03002.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population.

Authors:  M J Brisco; L W Tan; A M Orsborn; A A Morley
Journal:  Br J Haematol       Date:  1990-06       Impact factor: 6.998

Review 2.  Evolution of tumours and the impact of molecular oncology.

Authors:  G Klein; E Klein
Journal:  Nature       Date:  1985 May 16-22       Impact factor: 49.962

Review 3.  Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes.

Authors:  P Casali; A L Notkins
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

4.  Monoclonality in B-lymphoproliferative disorders detected at the DNA level.

Authors:  K J Trainor; M J Brisco; C J Story; A A Morley
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

5.  A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes.

Authors:  H K Adldinger; H Delius; U K Freese; J Clarke; G W Bornkamm
Journal:  Virology       Date:  1985-03       Impact factor: 3.616

6.  Different Epstein-Barr virus expression in lymphomas from immunocompromised and immunocompetent patients.

Authors:  B Borisch-Chappuis; C Nezelof; H Müller; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

Review 7.  Management of Epstein-Barr virus infections.

Authors:  J Andersson; I Ernberg
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

8.  Human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV) antigens and genome in lymph nodes of HIV-positive patients affected by persistent generalized lymphadenopathy (PGL).

Authors:  S Uccini; F Monardo; D Vitolo; A Faggioni; A Gradilone; A M Aglianó; V Manzari; L P Ruco; C D Baroni
Journal:  Am J Clin Pathol       Date:  1989-12       Impact factor: 2.493

9.  Epstein-Barr (EB) virus infection in homosexual men in London.

Authors:  D H Crawford; I Weller; V Iliescu; D W Wara
Journal:  Br J Vener Dis       Date:  1984-08

10.  Identification of EBV-DNA in lymph nodes from patients with lymphadenopathy and lymphomas associated with AIDS.

Authors:  B B Chappuis; H Müller; J Stutte; M M Hey; K Hübner; H K Müller-Hermelink
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1990
View more
  1 in total

1.  Increased expression of interferon-gamma in hyperplastic lymph nodes from HIV-infected patients.

Authors:  M J Boyle; M F Berger; M Tschuchnigg; J E Valentine; B G Kennedy; M Divjak; D A Cooper; J J Turner; R Penny; W A Sewell
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.